---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-054768"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T20:58:32.696177+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech appoints Lars Boesgaard as CFO; Matthew Hill resigns effective Dec 1, 2023

## Summary
- CFO Matthew Hill resigned effective Dec 1, 2023 to pursue other opportunities; no disagreement with company.
- Lars Boesgaard appointed CFO effective Dec 4, 2023; brings 25+ years healthcare finance experience.
- Employment agreement: $420,000 annual salary, 40% performance bonus, 12-month severance, COBRA reimbursement.
- Boesgaard receives inducement option for 200,000 shares vesting over four years.

## SEC filing metadata
- accession: 0001140361-23-054768
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/0001140361-23-054768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/ef20015466_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-054768
- JSON: https://secwatch.observer/filing/0001140361-23-054768.json
- Plain text: https://secwatch.observer/filing/0001140361-23-054768.txt

## Key facts
- Executive change
  Matthew Hill resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at PDS Biotechnology Corp.
  - Action: resigned
  - Role: Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  source text: On November 21, 2023, Matthew Hill submitted his resignation, effective December 1, 2023, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “ Company ”) in order to pursue other professional endeavors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/0001140361-23-054768-index.htm
- Executive change
  Lars Boesgaard was appointed as Chief Financial Officer at PDS Biotechnology Corp.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On November 28, 2023, the Company entered into an Executive Employment Agreement with Lars Boesgaard (the “ Employment Agreement ”), pursuant to which Mr. Boesgaard will assume the role of the Company’s Chief Financial Officer, effective as of December 4, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/0001140361-23-054768-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.